A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Orforglipron (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 26 Jun 2023 Results assessing the effect of food on OFG concentration in healthy adults presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 18 Feb 2022 Planned End Date changed from 7 Feb 2022 to 7 Apr 2022.